Implementing community-engaged pharmacogenomics in Indigenous communities

Katrina G Claw; Casey R Dorr; Erica L Woodahl

doi:10.1038/s41467-024-45032-5

Implementing community-engaged pharmacogenomics in Indigenous communities

Nat Commun. 2024 Jan 31;15(1):920. doi: 10.1038/s41467-024-45032-5.

Authors

Katrina G Claw¹, Casey R Dorr^{2

3

4

5}, Erica L Woodahl^{6

7}

Affiliations

¹ Department of Biomedical Informatics, Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. katrina.claw@cuanschutz.edu.
² Hennepin Healthcare Research Institute, Minneapolis, MN, USA.
³ Nephrology Division, Department of Medicine, Hennepin Healthcare, University of Minnesota, Minneapolis, MN, USA.
⁴ Experimental and Clinical Pharmacology Department, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
⁵ Clinical and Translational Sciences Institute, University of Minnesota, Minneapolis, MN, USA.
⁶ Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA.
⁷ L.S. Skaggs Institute for Health Innovation, University of Montana, Missoula, MT, USA.

Abstract

Innovative pharmacogenomic approaches (genetic variation related to medication response) are needed to reduce disease and disparities in Indigenous communities. We support community-based pharmacogenomics research, inclusive of Indigenous values and priorities, to improve the health and well-being of Indigenous peoples.

MeSH terms

Delivery of Health Care
Health Services, Indigenous*
Humans
Pharmacogenetics*

Abstract

MeSH terms

Grants and funding